Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AstraZeneca hit with setback as durvalumab falls further behind on lung cancer
AstraZeneca hit with setback as durvalumab falls further behind on lung cancer
AstraZeneca hit with setback as durvalumab falls further behind on lung cancer
Submitted by
admin
on December 19, 2015 - 11:28am
Source:
Fierce Biotech
News Tags:
AstraZeneca
durvalumab
PDL-1 inhibitors
lung cancer
Headline:
AstraZeneca hit with setback as durvalumab falls further behind on lung cancer
Do Not Allow Advertisers to Use My Personal information
